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A B S T R A C T   
Objective: Discovery of specific markers that reflect altered hepatic fatty acid oxidation could help to detect an 
individual’s risk of fatty liver, type 2 diabetes and cardiovascular disease at an early stage. Lipid and protein 
metabolism are intimately linked, but our understanding of this crosstalk remains limited. 
Methods: In male Wistar rats, we used synthetic fatty acid analogues (3-thia fatty acids) as a tool to induce hepatic 
fatty acid oxidation and mitochondrial biogenesis, to gain new insight into the link between fatty acid oxidation, 
amino acid metabolism and TCA cycle-related intermediate metabolites in liver and plasma. 
Results: Rats treated with 3-thia fatty acids had 3-fold higher hepatic, but not adipose and skeletal muscle, 
expression of the thioesterase 3-hydroxyisobutyryl-CoA hydrolase (Hibch), which controls the formation of 3- 
hydroxyisobutyrate (3-HIB) in the valine degradation pathway. Consequently, 3-thia fatty acid-stimulated he-
patic fatty acid oxidation and ketogenesis was accompanied by decreased plasma 3-HIB and increased methyl-
malonic acid (MMA) concentrations further downstream in BCAA catabolism. The higher plasma MMA 
corresponded to higher MMA-CoA hydrolase activity and hepatic expression of GTP-specific succinyl-CoA syn-
thase (Suclg2) and succinate dehydrogenase (Sdhb), and lower MMA-CoA mutase activity. Plasma 3-HIB corre-
lated positively to plasma and hepatic concentrations of TAG, plasma total fatty acids, plasma NEFA and insulin/ 
glucose ratio, while the reverse correlations were seen for MMA. 
Conclusion: Our study provides new insight into TCA cycle-related metabolic changes associated with altered 
hepatic fatty acid flux, and identifies 3-HIB and MMA as novel circulating markers reflective of mitochondrial 
β-oxidation in male Wistar rats.   
1. Introduction 
Altered mitochondrial function in liver, adipose and muscle tissue 
has been suggested to underlie the development of insulin resistance and 
increased risk of developing several diseases [1–4]. In situations of 
excess hepatic lipid uptake, an adaptive increase in mitochondrial 
oxidative capacity can prevent fatty liver and related conditions 
including insulin resistance and type 2 diabetes [5]. A better under-
standing of the molecular mechanisms underlying reduced hepatic fatty 
acid oxidation could help identify individuals with developing insulin 
resistance and facilitate early prevention and treatment. 
Metabolomic studies have revealed an elevation of fasting branched- 
chain amino acid (BCAA) concentrations in the circulation of people 
with obesity, insulin resistance and type 2 diabetes [6–9]. Circulating 
BCAA and metabolite concentrations depend on the net metabolism of 
BCAAs in several different tissues including liver, skeletal muscle, 
pancreas and adipose tissue [10]. Insulin resistance is associated with 
reduced BCAA catabolism in adipocytes [11,12] and a concomitant in-
crease in BCAA catabolism in skeletal muscle [10]. BCAAs provide 
substrates for the TCA cycle. Impaired oxidation of BCAAs may result in 
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excess accumulation of incompletely oxidized TCA intermediates and 
reduced fatty acid oxidation [13,14], and impaired flux of BCAAs into 
the TCA cycle has been linked to nonalcoholic fatty liver disease 
(NAFLD) [15]. We and others have recently reported altered levels of 
intermediary BCAA metabolites such as the valine-derived metabolite 3- 
hydroxyisobutyrate (3-HIB) in obesity, insulin resistance and type 2 
diabetes [16–21]. We found increased 3-HIB levels according to degree 
of hyperglycemia and in established type 2 diabetes, that adipocytes 
release 3-HIB, and that 3-HIB modulates mitochondrial respiration, 
insulin-stimulated glucose uptake and fatty acid uptake with different 
effects in white and brown adipocytes [21]. Another study found that 3- 
HIB can promote insulin resistance in skeletal muscle by increasing 
endothelial fatty acid uptake [22]. The release of 3-HIB and other TCA- 
related dicarboxylic acids depends on the removal of Coenzyme A (CoA) 
groups via specific thioesterases, a type of hydrolases. 
The 3-thia fatty acids, tetradecylthioacetic acid (TTA), 2-(tridec-12- 
yn-1-ylthio)acetic acid (1-triple TTA) and 1,10-biscarboxy-methylthio-
decane (BCMTD) were previously shown to increase the rate of mito-
chondrial fatty acid β-oxidation in the liver, while they are not 
β-oxidizable themselves [23]. The 3-thia fatty acids have been reported 
to lower triacylglycerol (TAG) levels both in liver and plasma through 
activation of the peroxisome proliferator-activated receptors (PPARs) 
and mitochondria transcription factor A (TFAM) and thereby increase 
mitochondrial fatty acid oxidation capacity [24–27]. We have previ-
ously observed that the TTA-induced increase in hepatic mitochondrial 
fatty acid oxidation runs in parallel with increased ketogenesis [24,26] 
and with expression of genes indicative of higher TCA cycle activity [26] 
and reduced gluconeogenesis [28]. Moreover, reduced body weight 
after long term administration of TTA was accompanied with increased 
plasma levels of several amino acids, possibly due to reduced amino acid 
catabolism, thereby transferring energy from lipids to amino acids [29]. 
While indirect evidence links BCAA metabolism, TCA cycle activity 
and fatty acid oxidation, and that this crosstalk is altered in insulin 
resistance [13], direct measurement of altered TCA cycle metabolites in 
plasma could provide important insight into the mechanisms that 
govern mitochondrial fatty acid oxidation in the liver, and reveal novel 
biomarkers of changes in these processes. Therefore, we here investi-
gated whether increased influx of fatty acids to the liver runs in parallel 
with changes in BCAAs catabolism reflected by changes in plasma 3-HIB 
and non-esterified fatty acids (NEFAs), liver and plasma triacylglycerols 
(TAGs), methylmalonic acid (MMA) and insulin/glucose ratio, as well as 
expression of genes and enzyme activities of regulatory proteins/ 
enzymes. 
2. Materials and methods 
2.1. Compounds 
In this study we used the synthetic fatty acid compounds 1-triple TTA 
(2-(tridec-12-yn-1-ylthio)acetic acid (CH ≡ C-(CH2)11-S-CH2-COOH)), 
TTA (tetradecylthioacetic acid (CH3-(CH2)13-S-CH2-COOH) and BCMTD 
(3-dithiacarboxylic acid (HOOC-CH2-S-(CH2)10-S-CH2-COOH). In these 
fatty acids, the C3 in the acyl chain is substituted with a sulphur atom, 
preventing them to undergo β-oxidation [23]. However, TTA can be 
degraded at the ω-end. In contrast, 1-triple TTA has a triple bond at the 
ω-end, making it non-degradable at both ends. BCMTD has a carboxyl 
group and a sulphur atom at the other end in the acyl chain as well, 
hindering it to be degraded at both ends [30]. Chemical structures of the 
synthetic fatty acids can be found in Supplementary Fig. 1. 
2.2. Animal care and treatment 
2.2.1. Animal study with 1-triple TTA 
5-Weeks-old male Wistar rats (Taconic, Ejby, Denmark) were ran-
domized on arrival by Research Randomizer [31] and housed in open 
cages in groups of four rats. In the 1-week acclimatization period and 
throughout the experiment, the rats were kept in standard 12 h light/12 
h dark cycles at 22 ± 2 ◦C and with humidity conditions of 55 ± 5% and 
had ad libitum access to standard chow diet and water. At the beginning 
of the experiment, the rats were block randomized to their respective 
treatments [31] and paired-housed separated by cage walls, enabling 
sniffing interaction. 0.5 ml 0.5% methylcellulose (Hospital Pharmacy, 
Bergen, Norway) with or without 0.02 g 1-triple TTA (Synthetica AS, 
Oslo, Norway) was given orally by gavage to the rats in their respective 
groups daily over the 3-week period. The rats in the control group and 1- 
triple TTA group were weighed once a day and weekly feed consumption 
was registered. At the end of the experiment, the rats were euthanized by 
5% isoflurane inhalation anaesthesia (Schering-Plough, Kent, UK) fol-
lowed by cardiac puncture. The collected EDTA-blood was immediately 
chilled on ice and plasma samples obtained by centrifugation were 
stored at − 80 ◦C. Liver, muscle and epididymal white adipose tissue 
(eWAT) were collected, weighed and snap-frozen in liquid nitrogen 
before storage at − 80 ◦C. Parts of the fresh liver samples were imme-
diately used for β-oxidation analysis (described later). Care was taken to 
improve the environment of the animals and to minimize suffering. The 
Norwegian State Board of Biological Experiments with Living Animals 
approved the protocol (Permit number 2015-7367). 
2.2.2. Animal study with TTA and BCMTD 
Male Wistar rats (Taconic, Ejby, Denmark), weighing 150–200 g, 
were paired-housed in wire cages. During the 1-week acclimatization 
period and throughout the experiment, the rats were kept in standard 12 
h light/12 h dark cycles at 20 ± 3 ◦C and had unlimited access to 
standard chow diet and water. Palmitic acid (control), TTA and BCMTD 
were dissolved in 0.5% sodium carboxymethyl cellulose (CMC) as pre-
viously described [32] and were given at doses of 150 and 300 mg/kg 
body weight in a volume of 0.7–1 ml by gastric intubation to the rats in 
their respective groups each day for 1 week. 0.5% CMC was in some 
cases used as a second control. All rats were weighed daily and feed 
consumption was registered weekly. At the end of the experiment, the 
rats were euthanized by subcutaneous injection of Hynorm (Janssen, 
Pharmaceutica NV, Beerse, Belgium) and Dormicum© (F. Hoffman-La- 
Roche Ltd., Basel, Switzerland) followed by cardiac puncture. The 
collected liver tissue samples were immediately chilled on ice. The use of 
animals in the study was approved by the local ethical committee for 
animal experiments based on the Guidelines for the Care and Use of 
Experimental Animals, and in agreement with the Norwegian laws and 
regulations on laboratory animals in research. 
2.3. Preparation of cellular fractions 
Liver tissue from each rat was homogenized in ice-cold homogeni-
zation buffer containing 0.25 M sucrose, 10 mM Hepes (pH 7.4) and 2 
mM EDTA. Subcellular fractions of the homogenate were prepared from 
each rat. The fractionation process was performed at 0–4 ◦C and con-
sisted of several centrifugation steps with different time integrals to 
obtain light-mitochondrial (peroxisome-enriched), microsomal and 
cytosolic fractions as described earlier [33]. Parts of light-mitochondrial 
(peroxisome-enriched) fractions were used to prepare pure peroxisome 
fractions as described elsewhere [34] with some modifications. 2 ml 
light-mitochondrial fraction was overlaid with 15 ml of 25% Nycodenz 
in 0.25 M sucrose, 1 mM EDTA and 10 mM Hepes (pH 7.4). After 
centrifugation at 106,000 ×g for 90 min, the upper debris layer was 
removed and the remaining pure peroxisome pellet was dissolved in 1 
ml 0.25 M sucrose, 1 mM EDTA and 10 mM Hepes (pH 7.4). 
2.4. Hepatic gene expression analysis 
Total RNA was isolated from frozen 20 mg frozen liver tissue by 
homogenization in RLT buffer (Qiagen) with 1% β-mercaptoethanol 
using TissueLyser II for 2 × 2 min at 25 Hz and by RNA purification using 
RNaesy Mini kit with DNase digestion (Qiagen), following the 
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manufacturer’s protocols. 500 ng RNA input was included in the cDNA 
synthesis using High Capacity cDNA Reverse Transcription Kits (Applied 
Biosystems). cDNA was mixed with 2× Taqman buffer (Applied Bio-
systems) and probes and primers (listed in Supplementary Table 1) and 
real-time quantitative PCR (RT-qPCR) was run on Sarstedt 384-well 
Multiply-PCR plates (Sarstedt Inc.) using the ABI Prism 7900HT 
Sequence detection system (Applied Biosystems). A standard curve was 
run for each probe by using a representative cDNA sample or cDNA from 
universal rat reference RNA (URRR, Agilent). mRNA levels were 
normalized to the reference gene Rplp0 or 18S. 
2.5. Muscle and adipose tissue gene expression analysis 
Total RNA was isolated from 100 mg frozen epididymal white adi-
pose tissue (eWAT) and 30 mg frozen muscle tissue using RNA/DNA/ 
Protein Purification Kit (Norgen Biotek Corp.) according to the manu-
facturer’s instructions. 127 ng purified RNA was used as template for 
cDNA synthesis, using the High Capacity cDNA reverse Transcription Kit 
(Applied Biosystems) in accordance with the supplier’s protocol. To 
analyze the cDNA, RT-qPCR was performed using LightCycler® 480 
SYBR Green I Master mix (Roche) and primers for genes of interest 
(listed in Supplementary Table 2), following the manufacturer’s proto-
col. mRNA levels were based on standard curves or the delta-delta Ct 
method and was normalized to the reference gene Rplp0. 
2.6. Measurement of methylmalonyl-CoA mutase mRNA expression by 
hybridization analysis 
Total RNA was purified by the guanidinium thiocyanate technique as 
previously described [35]. Gel electrophoresis on a 1% agarose mini-gel 
followed by ethidium bromide staining was carried out to evaluate the 
degree of RNA digestion. Previously described methods for RNA slot 
blotting onto nylon membranes [36] and hybridization to immobilized 
RNA [37] were followed. The relative mRNA expression of 
methylmalonyl-CoA was based on hybridization of radioactive probe to 
each RNA sample and was normalized to 28S RNA. The cDNA fragment 
of methylmalonyl-CoA was 32P-labelled using the oligolabelling method 
[38]. 
2.7. Quantification of plasma and liver lipids 
Lipids were extracted from frozen liver tissue as previously described 
[39]. Before the measurements, the lipid extract was evaporated with 
nitrogen and redissolved in isopropanol. Enzymatic measurements of 
lipids in liver and plasma samples were analyzed by the Hitachi 917 
system (Roche Diagnostics) using the Triglyceride kit by GPO-PAP 
method (Roche Diagnostics) and NEFA FS kit (Diagnostic Systems). 
2.8. Plasma glucose and insulin measurements 
Glucose concentration in plasma was determined enzymatically by 
the Hitachi 917 system (Roche Diagnostics) using the GLUC2 kit (Roche 
Diagnostics). Insulin measurements in plasma were performed using the 
Rat/Mouse insulin ELISA kit (Merck). 
2.9. Quantification of ketone body in plasma 
Production of ketone bodies was determined in plasma samples using 
a β-hydroxybutyrate (ketone body) colorimetric assay kit (Cayman 
Chemical). 
2.10. Hepatic mitochondrial fatty acid oxidation (β-oxidation analysis) 
1 g fresh liver tissue was homogenized in 4 ml ice-cold buffer 
comprising 0.25 M sucrose, 10 mM Hepes and 1 mM Na4EDTA (pH 7.4). 
The homogenates were centrifuged at 1030 RCF for 10 min at 4 ◦C, and 
the post-nuclear fraction was immediately used to measure palmitoyl- 
CoA oxidation as acid-soluble products, as described earlier [40]. The 
protein concentration was measured by the DC Protein Assay kit (Bio- 
Rad Laboratories). 
2.11. Measurement of plasma amino acids and related metabolites 
Metabolites and amino acids in plasma were measured by gas 
chromatography-tandem mass spectrometry (GC–MS/MS) at Bevital AS 
(Bergen, Norway; http://www.bevital.no) as earlier described [41]. 
2.12. Measurement of serum MMA and vitamin B12 levels 
Methylmalonic acid (MMA) concentrations in serum samples were 
determined by capillary electrophoresis (CE) as previously described 
[42]. Vitamin B12 levels were measured using the competitive magnetic 
separation immunoassay by Technican Immuno 1® System (1995) 
(Bayer Corporation). 
2.13. Measurements of free coenzyme A (CoASH), propionyl-CoA, 
methylmalonyl-CoA, and succinyl-CoA 
The concentrations of short-chain acyl-CoA esters in liver tissue 
samples were quantified by reversed-phase high performance liquid 
chromatography (RP-HPLC) as described previously [43] with some 
modifications. Liver tissue was homogenized in ice-cold 5% sulfosali-
cylic acid containing 50 μM dithioerythritol to obtain 30% w/v ho-
mogenates. 500 μl homogenate was centrifuged at 600 ×g for 10 min 
and 50 μl supernatant was immediately transferred into a 100 × 4.6 mm 
HPLC column packed with 3-μm particle size of ODS Hypersil (C18), 
equipped with a guard column filled with Pelliguard LC-18 packing. 
Absorbance was measured at 254 nm. Elution solvent A consisted of 100 
mM sodium phosphate and 75 mM sodium acetate (pH 4.6) and solvent 
B contained 70% solvent A in methanol. The elution process was per-
formed at room temperature and the flow rate was 1.5 ml/min. The 
following elution profile was obtained: 0 min, 90% A; 10 min, 60% A; 
17.6 min, 10% A, and the baseline condition was achieved by washing 
the column with 90% A for 8 min. 
2.14. Enzymatic assays in liver fractions 
Propionyl-CoA synthetase activity was measured as previously 
described [44]. A linear relationship between time (0–30 min) and 
protein (0–1 mg/assay) was observed in the assay. 
Propionyl-CoA carboxylase activity was determined as previously 
described [45] with some modifications. The assay mixture consisted of 
1.30 mM propionyl-CoA, 68 mM Tris-HCl (pH 8), 3 mM MgCl2, 100 mM 
KCl, 1.35 mM ATP, 1 μCi (14C) 20 mM NaHCO3, and 0.05–0.2 mg pro-
tein. Incubations were carried out in duplicates for 30 min at 37 ◦C. 
Control incubations contained no propionyl-CoA. 25 μl 5 M perchloric 
acid was used to stop the reactions, followed by centrifugation at 1700 
×g for 15 min. 25 μl supernatant was transferred onto Whatman 3MM 
paper and was dried overnight. Measurements of radioactivity were 
performed on the paper filters. 
Methylmalonyl-CoA mutase activity was measured as the generation 
of (2-(3)-14C)-succinyl-CoA from a racemic mixture of DL-(methyl-14C)- 
methylmalonyl-CoA as described before [46]. Assays where the rats 
were fed palmitate alone (200 mg/kg body weight/day) had 20–100 μM 
palmitoyl-CoA and CoA-bound TTA, and identical concentrations of the 
free corresponding fatty acids (not CoA-bound). 
Methylmalonyl-CoA hydrolase was based on the release of free 
CoASH from methylmalonyl-CoA and was measured spectrophotomet-
rically with 5,5′-dithio-bis(2-nitrobenzoic acid) (DTNB) as described 
earlier [47]. The assay mixture contained 0.285 μM Methylmalonyl- 
CoA, 11.5 mM Hepes (pH 6.8), 0.24 mM DTNB, and 120 mM KCl. A 
linear relationship in the spectrophotometric assay was seen up to 250 
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μg of protein added. 
Methylmalonyl-CoA, propionyl-CoA, and DTNB were obtained from 
Sigma Chemicals. All other chemicals used were purchased from com-
mon commercial sources and were of analytic grade. 
2.15. Statistical analyses 
Statistical analyses were performed using the software GraphPad 
Prism 8. To evaluate significant difference between two groups, two- 
tailed unpaired t-tests (assuming normal distribution) were performed. 
Ordinary one-way ANOVA (Sidak’s post-hoc test) was performed to 
assess significant difference for more than two groups. Two-way ANOVA 
(Holm-Sidak’s post-hoc test) was used to evaluate control and treatment 
groups for the different compartments in the subcellular liver fractions. 
Significant difference was defined as p < 0.05 and results are expressed 
as mean ± S⋅D. for 5–8 rats per group. Correlations were calculated by 
Spearman. 
3. Results 
3.1. Effects on fatty acid flux into liver and BCAA metabolites 
We first investigated the impact of 3-thia fatty acid administration on 
hepatic fatty acid flux and plasma concentrations of BCAA metabolites. 
Three weeks of 1-triple TTA treatment led to increased hepatic gene 
expression of carnitine/acylcarnitine translocase (Slc25a20) (Fig. 1), 
together with increased expression of fatty acid transfer protein (Cd36), 
fatty acid binding protein 1 (Fabp1) and carnitine transporter (Slc22a5) 
as reported previously [26]. This was accompanied with increased 
expression of the gene encoding ELOVL fatty acid elongase 6 (Elovl6) 
(Fig. 1), which uses malonyl-CoA as a 2‑carbon donor in the first and 
rate-limiting step of fatty acid elongation. This was further accompanied 
by decreased levels of plasma non-esterifies fatty acid (NEFA), decreased 
total fatty acids in plasma, increased levels of the plasma ketone bodies/ 
total fatty acid ratio and decreased insulin/glucose ratio, but no differ-
ence in body weight gain or feed efficiency as reported previously 
[26,28]. 
Metabolites from BCAA degradation, including 3-HIB and MMA, may 
enter the TCA cycle as acetyl-CoA or succinyl-CoA (Fig. 2A). 1-triple TTA 
treatment did not change the circulating levels of valine, leucine and 
isoleucine, but the plasma levels of 3-HIB and MMA were decreased and 
increased respectively (Fig. 2B), reflected in a strong inverse correlation 
between 3-HIB and MMA (Fig. 2C). 
3.2. Effects on regulatory enzymes in BCAA catabolism 
In 1-triple TTA-treated rats the gene expressions of Bcat2, Bckdha and 
Hibadh in liver, muscle and adipose tissue remained unchanged by 1-tri-
ple TTA administration (Fig. 2D). Interestingly, hepatic expression of 
Hibch, encoding a mitochondrially located enzyme which hydrolyzes 3- 
hydroxyisobutyryl-CoA to 3-HIB, was increased 3-fold (Fig. 2D). The 
effect of 1-triple TTA on tissue 3-HIB formation may be specific for liver, 
since no changes in Hibch expression were seen in samples from muscle 
and epididymal fat (Fig. 2D). 
3.3. Correlations of 3-HIB with changes in mitochondrial functions and 
parameters linked to lipid and glucose metabolism 
The mitochondrial fatty acid oxidation increased after treatment 
with 1-triple TTA [26], and both plasma levels of 3-HIB and 3-HIB/ 
MMA-ratio were negatively correlated with mitochondrial fatty acid 
oxidation across the control and treatment groups (Fig. 2E, Supple-
mentary Table 3). On the other hand, plasma level of 3-HIB correlated 
positively to both plasma and liver TAG, and plasma total fatty acids and 
NEFA (Fig. 3A). Additionally, both plasma levels of 3-HIB and 3-HIB/ 
MMA-ratio were correlated inversely to hepatic total fatty acid levels 
and plasma ketone/NEFA ratio, an indicator of fatty acid oxidation and 
ketogenesis in the liver (Fig. 3A, Supplementary Table 3). In the 1-triple 
TTA-treated rats, the plasma ratio of insulin/glucose was lower than in 
controls [28]. Notably, the insulin/glucose ratio was positively corre-
lated to both 3-HIB, TAG and NEFA (Fig. 3B). Similarly, across the 
groups we also found significant correlations between MMA and/or 3- 
HIB/MMA ratio with the parameters of lipid and glucose metabolism 
(Supplementary Table 3). 
3.4. Degradation of hepatic 3-HIB 
The strong correlations between circulating 3-HIB and several pa-
rameters in lipid and glucose metabolism prompted us to further 
investigate the enzymatic processes that regulate 3-HIB metabolism and 
degradation in the liver. 3-HIB can be converted to propionyl-CoA and 
CoASH by HIBADH and ALDH6A1 via the intermediate metabolite MMS 
(Fig. 2A). Interestingly, the hepatic concentrations of both free CoASH 
and propionyl-CoA were increased by TTA and BCMTD administration 
(Fig. 4A). We also observed higher hepatic concentrations of MMA-CoA 
in TTA-treated rats than in controls (Fig. 4A). 
Propionyl-CoA is formed by degradation of valine and leucine, as 
well as of odd-chain fatty acids, but can also be converted from propi-
onate and CoASH by propionyl-CoA synthetase (Fig. 2A). Propionyl-CoA 
can further be converted to MMA-CoA by propionyl-CoA carboxylase. In 
post-nuclear fractions of rats treated with BCMTD, we found increased 
activity of propionyl-CoA synthetase, but no change in propionyl-CoA 
carboxylase activity (Fig. 4B). Moreover, MMA-CoA can be converted 
to MMA by MMA-CoA hydrolase or to succinyl-CoA by MMA-CoA 
mutase (Fig. 2A). We observed a decrease in MMA-CoA mutase activ-
ity and an increase in MMA-CoA hydrolase activity by BCMTD treatment 
(Fig. 4B). In subcellular fractions from the liver, we observed that most 
of the activity of MMA-CoA mutase was located to the mitochondrial and 
cytosolic fractions, showing decreased mutase activity by BCMTD 
(Fig. 4C). Low mutase enzyme activities were found in the pure perox-
isomal fraction, the peroxisome-enriched fractions containing peroxi-
somes and lysosomes, and in the microsomal fractions (Fig. 4C). Most of 




























Fig. 1. Effects of 1-triple-TTA on genes regulating fatty acid flux into the liver 
in vivo. 
Relative hepatic mRNA expression of Slc25a20 and Elovl6, relative to Rplp0 in 
control (n = 7) and 1-triple TTA-treated Male Wistar rats (n = 7). The results 
are presented as mean ± SD. 
*p < 0.05, **p < 0.01, ***p < 0.001. 
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mitochondrial and cytosol fractions, and the hydrolase activity was 
increased in these fractions after BCMTD administration (Fig. 4C). The 
microsomal fraction had only diminutive levels of hydrolase activity 
(Fig. 4C). Although the mutase activities both in mitochondria- and 
cytosol-enriched fractions were decreased (Fig. 4C), the hepatic mRNA 
levels of MMA-CoA mutase were elevated 1.5–2-fold by TTA and 
BCMTD treatment (Fig. 4D). We also observed higher circulating con-
centrations of MMA in TTA-treated rats although a tendency of lower 
MMA concentrations in BCMTD-treated rats, while serum vitamin B12 
levels were lower in both TTA- and BCMTD-treated rats (Fig. 4E). 
We further investigated the metabolite flux from BCAA degradation 
towards the TCA cycle in the liver, by measuring the gene expression of 
key enzymes involved. Aldh6a1, which is responsible for conversion 
between (S)-MMS and and propionyl-CoA, showed no difference in 
expression between treated and untreated rats (Fig. 4F). Of interest, the 
hepatic gene expression of methylmalonyl-CoA synthetase (Acsf3), 
which converts MMA to (R)-MMA-CoA, was upregulated by 1-triple TTA 
(Fig. 4F). The expression of the genes Pcca and Pccb, which together 
encode the enzyme propionyl-CoA carboxylase, was also increased in 
the liver by 1-triple TTA (Fig. 4F). We additionally observed increased 
expression of methylmalonyl-CoA emirase (Mcee), which is responsible 




































































































































































































Fig. 2. Comparison of liver, muscle and fat in BCAA metabolism and the effect of 1-triple TTA on fatty acid oxidation in the liver in vivo. 
(A) Overview of cellular BCAA catabolism and TCA cycle. Amino acids, metabolites and intermediates are marked in blue and relevant enzymes in green. (B) Plasma 
levels of 3-HIB, MMA and the BCAAs (valine, leucine and isoleucine) in control (n = 7) and 1-triple TTA-treated Male Wistar rats (n = 7). (C) Spearman correlations 
for plasma 3-HIB and plasma MMA concentrations in control (n = 7) and 1-triple TTA-treated Male Wistar rats (n = 7). Spearman r and p-value stated in the figures. 
(D) Relative mRNA expression of genes encoding enzymes in BCAA catabolism (relative to Rplp0) in liver, muscle and epididymal white adipose tissue dissected from 
1-triple TTA-treated Male Wistar rats (n = 7) relative to control (n = 7). The results are presented as mean ± SD. (E) Spearman correlations of plasma 3-HIB 
concentration and liver β-oxidation in control (n = 7) and 1-triple TTA-treated Male Wistar rats (n = 7). Spearman r and p-value stated in the figures. 
*p < 0.05, **p < 0.01, ***p < 0.001. 
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rats (Fig. 4F). An increase in hepatic Mut expression was also seen in 1- 
triple TTA-treated rats (Fig. 4F). 
The liver concentrations of succinyl-CoA were not significantly 
changed by TTA or BCMTD treatment (Fig. 4A). However, an increased 
level of plasma succinate in 1-triple TTA-treated rats was accompanied 
with increased expression of genes encoding both GTP-specific succinyl- 
CoA synthetase (Suclg2), succinate dehydrogenase (Sdha) and the iron- 
sulphur subunit of succinate dehydrogenase (Sdhb), the latter involved 
in complex II of the mitochondria electron transport chain and respon-
sible for transferring electrons from succinate to ubiquinone (Fig. 4F). 
Furthermore, plasma succinate levels were inversely correlated to 
circulating 3-HIB levels (Fig. 4G). 
4. Discussion 
In this study, we used mitochondria-targeted fatty acid analogues as 
tools to investigate BCAA catabolism and cellular mechanisms related to 
TCA cycle activity, mitochondrial β-oxidation and lipid metabolism 
relevant in progression of metabolic diseases. We observed that treat-
ment of rats with these liver-targeting compounds reduced plasma levels 
of 3-HIB and increased plasma levels of MMA. Previous studies have 
reported that 3-HIB is released from different tissues such as muscle, 
heart and adipocytes and acts as a signaling molecule [21,22,48,49]. 
However, as the fatty acid analogues used in this study primarily target 
the liver mitochondria, our results indicate that the circulating levels of 
3-HIB and MMA may be controlled, at least in part, by the liver, which 
also has high BCAA catabolic activity [10]. In line with this, 3-thia fatty 
acid treatment altered gene expression and activity of BCAA 
catabolizing enzymes in the liver, while no such changes were found in 
skeletal muscle and epididymal white adipose tissue. 
The reduced plasma levels of 3-HIB in 3-thia fatty acid-treated rats 
might have resulted from increased 3-HIB catabolism towards the TCA 
cycle. This is supported by the higher liver content of free CoASH, 
propionyl-CoA and succinyl-CoA, higher MMA-CoA hydrolase activity, 
and higher gene expression of MMA-CoA mutase, succinyl-CoA synthase 
and succinate dehydrogenase compared to control. Of note, even though 
treatment with 3-thia fatty acids increased expression of the gene 
encoding MMA-CoA mutase, thereby promoting formation of the TCA- 
cycle intermediate succinyl-CoA, we found a decrease in MMA-CoA 
mutase activity. Still, the tendency towards increased hepatic succinyl- 
CoA levels was accompanied with increased plasma levels of succi-
nate, indicating an increased degradation of BCAA intermediates that 
can be used as fuel in the TCA cycle. 
Numerous studies have shown increased circulating BCAA concen-
trations in obesity and insulin resistance [6–8]. Of note, the 3-thia fatty 
acid-induced increase in circulating levels of BCAA metabolites was not 
accompanied with reduced BCAA levels. However, the present study 
indicates that downstream intermediates in BCAA metabolism, here 
most notably 3-HIB and MMA, are direct and specific reflectors of 
altered cellular functions. This is supported by our recent study showing 
specific changes in circulating 3-HIB and not valine within 1 week after 
bariatric surgery [21], and another previous study showing a correlation 
of 3-HIB, but not of the BCAAs, and improvements in glucose meta-
bolism following dietary intervention [19]. Notably, a recent study 
showed that whole-body knockout of the mitochondrial BCAA catabolic 
enzyme BCKDH kinase in mice increased circulating 3-HIB 
Fig. 3. Plasma 3-HIB levels correlates with changes in mitochondrial functions and parameters linked to lipid and glucose metabolism. 
(A–B) Spearman correlations of plasma 3-HIB concentrations and parameters related to lipid and glucose metabolism in control (n = 7) and 1-triple TTA-treated Male 
Wistar rats (n = 7). 
TAG; triacylglycerol, NEFA; non-esterified fatty acids. 
Spearman r and p-values are stated in the figures. 
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concentrations while decreasing circulating valine [10]. Additionally, 
the authors reported that mice with obesity and insulin resistance show 
a redistribution in whole-body BCAA metabolism, with a shift in BCAA 
oxidation from fat and liver towards skeletal muscle, concomitant with 
elevated circulating BCAA levels [10]. Together, these studies reveal a 
complex inter-organ regulation of BCAA metabolism, and together with 
our data support that specific BCAA-related metabolites may capture 
altered cellular and physiological states, such as fatty acid oxidation, 
more directly than the BCAAs. 
The present study implicates 3-HIB as a reflector of, and potential 
player in, fatty acid oxidation, ketogenesis and glucose production and 
storage, metabolic processes in which the liver plays an essential role 
[50]. The plasma levels of 3-HIB showed significant positive correlations 
to both plasma and liver TAG as well as to plasma total fatty acids and 
NEFA, and inverse associations with hepatic β-oxidation and to plasma 
ketone/NEFA ratio. Mitochondrial fatty acid oxidation has previously 
been implicated in the regulation of both liver and plasma TAG [24–27]. 
The altered expression of the 3-HIB-forming enzyme HIBCH in the liver 
but not adipose and muscle tissue suggests that 3-HIB may serve as a 
marker of altered hepatic fatty acid metabolism. Measurement of 3-HIB 
might therefore have clinical value with respect to monitoring patients 
at risk of developing fatty liver and related insulin resistance due to 
impaired hepatic fatty acid oxidation and altered BCAA catabolism. 
Although we here analyzed changes in 3-HIB in rats with pharmaco-
logically activated fatty acid oxidation and ketogenesis, we and others 
have previously demonstrated a marked increase in circulating 3-HIB 
levels in the context of obesity and insulin resistance [16–21]. Our 
study therefore suggests that high circulating 3-HIB levels in these 
conditions reflect reduced hepatic fatty acid oxidation, and that thera-
pies that lower 3-HIB levels might act at least in part by increasing fatty 
acid oxidation. These possibilities however need to be tested in future 
studies. Conversely, it is of interest to test if 3-HIB blocks fatty acid 
Fig. 4. 3-Thia fatty acids affect pathways of hepatic BCAA catabolism and 3-HIB degradation. 
(A) Levels of various short chain acyl-CoA derivatives in liver homogenates of rats treated with TTA (n = 5) or BCMTD (n = 5) for 7 days. The results are presented as 
mean ± S.D. (One-way ANOVA, Sidak’s). (B) Effect of BCMTD on the activity of main enzymes in propionyl-CoA metabolism linked to the BCAA pathway, measured 
in post nuclear liver fractions of rats treated for 7 days. The results are presented as mean ± S.D. of 5 animals per group. Treatment doses for palmitic acid and 
BCMTD were 300 ng/kg body weight/day. (C) Specific activities of methylmalonyl-CoA mutase and methylmalonyl-CoA hydrolase in each of the subcellular liver 
fractions from rats treated with or without BCMTD for 7 days. Treatment doses for palmitic acid and BCMTD were 300 ng/kg body weight/day. The results are 
presented as mean ± S.D. of 5 animals per group (Two-way ANOVA, Holm-Sidak’s). (D) Effect of TTA on the mRNA expression of methylmalonyl-CoA mutase in rat 
liver. Animals were treated with 2 doses of TTA. One representative slot blot of a total of four is shown. Cumulative results of slot blots are shown in the graph. 
Results represent means ± S.D. of four animals. (E) Levels of MMA and vitamin B12 in serum of rats treated with 300 mg/kg/day of palmitic acid (control), TTA or 
BCMTD for 7 days. The results are presented as mean ± S.D. of 5 animals per group (One-way ANOVA, Sidak’s). (F) Relative hepatic gene expression of key enzymes 
of the BCAA pathway in the direction to the TCA cycle, relative to 18S in control (n = 7) and 1-triple TTA-treated Male Wistar rats (n = 7). The results are presented 
as mean ± SD. (G) Plasma levels of succinate, and Spearman correlation for plasma 3-HIB and plasma succinate concentrations in control (n = 7) and 1-triple TTA- 
treated Male Wistar rats (n = 7). Spearman r and p-values are stated in the figures. 
*p < 0.05, **p < 0.01, ***p < 0.001. 
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oxidation and ketogenesis in the liver. 
Our study points to a mechanism of increased circulating MMA 
concentrations in the context of increased hepatic fatty acid oxidation 
that is at least in part independent of vitamin B12 activity, as circulating 
vitamin B12 levels were decreased by 3-thia fatty acid treatment. MMA- 
CoA mutase, which is responsible for converting MMA-CoA to succinyl- 
CoA, is a vitamin B12-dependent protein, and high MMA levels are used 
as an indicator of vitamin B12 deficiency [51]. Long-term use of met-
formin, a first-line pharmacologic treatment of type 2 diabetes which is 
thought to improve mitochondrial function [52,53], has been found to 
promote vitamin B12 deficiency accompanied by increased plasma 
MMA levels [54,55]. Elevated MMA levels are also observed in patients 
with the genetic disorder methylmalonic aciduria, which can be caused 
by mutations in the gene that encodes the MMA-CoA mutase and result 
in disturbed amino acid metabolism [56]. Circulating MMA levels are 
therefore though to largely depend on the activity of the B12-dependent 
MMA-CoA mutase. Additionally, impairment of MMA-CoA mutase has 
been found to result in mitochondrial dysfunction and altered lipid 
metabolism in skeletal muscle [14]. However, recent studies have also 
demonstrated that circulating MMA levels can be affected via the valine 
degradation pathway by heritability of specific HIBCH variants, inde-
pendently of the level of coenzyme B12 [57,58], and that this mecha-
nism also involves impaired mitochondrial function [58]. In the present 
study, gene expression of Hibch, encoding 3-hydroxyisobutyate-CoA 
hydrolase which can support MMA formation by generating free 3- 
HIB, increased 3-fold in liver after 1-triple TTA administration. Our 
study further supports the importance of the B12-independent enzyme 
MMA-CoA hydrolase in this context. MMA-CoA hydrolase is responsible 
for splitting off CoA from MMA-CoA, and thereby controls the produc-
tion of MMA [59]. Indeed, we observed a marked increase in the enzyme 
activity of MMA-CoA hydrolase by 3-thia administration in rats, while 
MMA-CoA mutase activity surprisingly decreased. Taken together, these 
data support that the altered circulating MMA levels could primarily be 
due to the increased hepatic Hibch expression as well as increased MMA- 
CoA hydrolase activity observed upon 3-thia fatty acid treatment in the 
present study, independent of vitamin B12. 
Our study has some limitations. First, our observations were made in 
male rats, and we cannot necessarily extrapolate the findings to female 
rats, or to humans. Additionally, the experiments were performed in 
lean insulin sensitive and not also in obese/insulin resistant rats. 
Moreover, the data represent the net whole-body metabolic effect of the 
3-thia fatty acids, and although these compounds primarily target fatty 
acid oxidation in the liver [26], we did not trace intracellular or whole- 
body fluxes of BCAA and TCA cycle intermediates. The relationship 
between BCAAs, the TCA cycle and fatty acid metabolism is complex. 
BCAAs and fatty acids function in a cooperative manner with effects on 
mitochondrial biogenesis, glycolysis, and insulin signal transduction, 
but the primary mechanisms and complex cross-tissue regulation un-
derlying altered insulin sensitivity and mitochondrial dysfunction 
remain unclear [13,60]. 
In conclusion, the present study shows that enhanced mitochondrial 
β-oxidation, induced by 3-thia fatty acids that target the liver, is 
accompanied by lower plasma levels of 3-HIB and higher plasma levels 
of MMA and succinate. These changes correspond to altered hepatic 
expression and activity of 3-HIB-CoA and MMA-CoA-targeting thio-
esterases which remove the CoA moieties from intermediary metabolites 
linked to BCAA catabolism and the TCA cycle. Our data support 3-HIB 
and MMA as novel circulating markers of altered hepatic mitochon-
drial fatty acid oxidation, at least in male Wistar rats. 
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